- Home
- AZI vs GRI Comparison
AZI vs GRI Comparison
Compare AZI & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AZI | GRI |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | China | United States |
| Employees | 53 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 3.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AZI | GRI |
|---|---|---|
| Price | $1.46 | $1.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | ★ 7.7M | 91.5K |
| Earning Date | 02-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.03 | $0.18 |
| 52 Week High | $7.00 | $6.70 |
Technical Indicators
Market Signals| Indicator | AZI | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 38.18 |
| Support Level | $0.17 | $1.78 |
| Resistance Level | $1.45 | $1.89 |
| Average True Range (ATR) | 0.68 | 0.17 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 7.18 | 12.96 |
Price Performance
Historical ComparisonAbout AZI Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
Autozi Internet Technology (Global) Ltd provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels in China. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, it has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the auto parts & auto accessories sales.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.